ArticleCardiovascular and interventional radiology2022
Long-Term Efficacy and Recurrence Prediction of Prostatic Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Article in Cardiovascular and interventional radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Commentary on "Three-Month Magnetic Resonance Imaging Post-prostate Artery Embolization Predicts 1-Year Clinical Outcomes".Cardiovascular and interventional radiology · 2026Article
- Promising Minimally Invasive Option Emerging in the Treatment of Benign Prostatic Obstruction: Prostatic Artery Embolization.Journal of clinical medicine · 2025Review
- Predicting Early Outcomes of Prostatic Artery Embolization UsingDiagnostics (Basel, Switzerland) · 2025Article
- A Patient with Benign Prostatic Hyperplasia Treated with Prostatic Arterial Embolization: Case-report with Review of the Literature from Asia.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025Review
- Safety and Clinical Efficacy of Prostatic Artery Embolization in Patients with Indwelling Urinary Catheter for Benign Hyperplasia-A Multicenter Study.Diagnostics (Basel, Switzerland) · 2024Article
- Commentary on "Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study".Cardiovascular and interventional radiology · 2024Article
- Prostate volume: does it predict patient outcomes following prostate artery embolisation? A retrospective cohort study.CVIR endovascular · 2024Article
- Benefits and advances of Cone Beam CT use in prostatic artery embolization: review of the literature and pictorial essay.CVIR endovascular · 2024Review
- Benefits of Repeat Prostatic Artery Embolization on Persistent or Recurrent Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia.Cardiovascular and interventional radiology · 2023Article
- Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization.CVIR endovascular · 2023Article
- Controversies in Prostate Artery Embolization: Future Best Practice.Seminars in interventional radiology · 2022Review
- Long-Term PAE Results: What Do We Know.Seminars in interventional radiology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the efficacy of prostatic artery embolization (PAE) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) during long-term follow-up and analyze predictors related to LUTS recurrence.
methodsThis was a single-center retrospective study involving 125 BPH patients with LUTS who underwent PAE from February 2014 to February 2020. The median follow-up was 36 months. Clinical success was defined as reductions in the International Prostate Symptom Score (IPSS) and quality of life (QoL) score and no need for any other treatment for LUTS; otherwise, it was regarded as a clinical failure. Recurrence was defined as a clinical failure that occurred after an initial success. Cumulative clinical success rates, recurrence rates and re-intervention rates were evaluated. Friedman test was performed to compare differences in IPSS, QoL and prostatic volume (PV) among baseline and follow-up times. Predictors for LUTS recurrence were analyzed with the univariate and multivariate Cox regression model.
resultsTechnical success (bilateral PAE) rate was 92.8% (116/125). Significant differences in IPSS, QoL and PV were observed between baseline and follow-up time points (P < 0.001). The cumulative clinical success rates at 2, 3, 4 and 5 years were 82.4%, 65.5%, 52.4% and 37.4%. The cumulative recurrence rates and re-intervention rates at 1, 2 and 5 years were 6.8%, 12.7%, 60.4% and 5.9%, 10.2%, 50.8%, respectively. Unilateral PAE was an significant predictor of recurrence (P < 0.05).
conclusionsPAE is an effective treatment option for LUTS. Unilateral PAE is a significant independent predictor of LUTS recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.